Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 72

1.

MANF regulates metabolic and immune homeostasis in ageing and protects against liver damage.

Sousa-Victor P, Neves J, Cedron-Craft W, Ventura PB, Liao CY, Riley RR, Soifer I, van Bruggen N, Kolumam GA, Villeda SA, Lamba DA, Jasper H.

Nat Metab. 2019 Feb;1(2):276-290. doi: 10.1038/s42255-018-0023-6. Epub 2019 Jan 14.

2.

The future of humans as model organisms.

FitzGerald G, Botstein D, Califf R, Collins R, Peters K, Van Bruggen N, Rader D.

Science. 2018 Aug 10;361(6402):552-553. doi: 10.1126/science.aau7779. No abstract available.

PMID:
30093589
3.

RIPK3 deficiency or catalytically inactive RIPK1 provides greater benefit than MLKL deficiency in mouse models of inflammation and tissue injury.

Newton K, Dugger DL, Maltzman A, Greve JM, Hedehus M, Martin-McNulty B, Carano RA, Cao TC, van Bruggen N, Bernstein L, Lee WP, Wu X, DeVoss J, Zhang J, Jeet S, Peng I, McKenzie BS, Roose-Girma M, Caplazi P, Diehl L, Webster JD, Vucic D.

Cell Death Differ. 2016 Sep 1;23(9):1565-76. doi: 10.1038/cdd.2016.46. Epub 2016 May 13.

4.

Sustained Brown Fat Stimulation and Insulin Sensitization by a Humanized Bispecific Antibody Agonist for Fibroblast Growth Factor Receptor 1/βKlotho Complex.

Kolumam G, Chen MZ, Tong R, Zavala-Solorio J, Kates L, van Bruggen N, Ross J, Wyatt SK, Gandham VD, Carano RA, Dunshee DR, Wu AL, Haley B, Anderson K, Warming S, Rairdan XY, Lewin-Koh N, Zhang Y, Gutierrez J, Baruch A, Gelzleichter TR, Stevens D, Rajan S, Bainbridge TW, Vernes JM, Meng YG, Ziai J, Soriano RH, Brauer MJ, Chen Y, Stawicki S, Kim HS, Comps-Agrar L, Luis E, Spiess C, Wu Y, Ernst JA, McGuinness OP, Peterson AS, Sonoda J.

EBioMedicine. 2015 May 30;2(7):730-43. doi: 10.1016/j.ebiom.2015.05.028. eCollection 2015 Jul.

5.

FDG-PET imaging for oxidized LDL in stable atherosclerotic disease: a phase II study of safety, tolerability, and anti-inflammatory activity.

Lehrer-Graiwer J, Singh P, Abdelbaky A, Vucic E, Korsgren M, Baruch A, Fredrickson J, van Bruggen N, Tang MT, Frendeus B, Rudd JHF, Hsieh F, Ballantyne CM, Ghoshhajra B, Rosenson RS, Koren M, Roth EM, Duprez DA, Fayad ZA, Tawakol AA.

JACC Cardiovasc Imaging. 2015 Apr;8(4):493-494. doi: 10.1016/j.jcmg.2014.06.021. Epub 2014 Nov 12. No abstract available.

6.

Interleukin-22 alleviates metabolic disorders and restores mucosal immunity in diabetes.

Wang X, Ota N, Manzanillo P, Kates L, Zavala-Solorio J, Eidenschenk C, Zhang J, Lesch J, Lee WP, Ross J, Diehl L, van Bruggen N, Kolumam G, Ouyang W.

Nature. 2014 Oct 9;514(7521):237-41. doi: 10.1038/nature13564. Epub 2014 Aug 6.

PMID:
25119041
7.

Systemic VEGF-A neutralization ameliorates diet-induced metabolic dysfunction.

Wu LE, Meoli CC, Mangiafico SP, Fazakerley DJ, Cogger VC, Mohamad M, Pant H, Kang MJ, Powter E, Burchfield JG, Xirouchaki CE, Mikolaizak AS, Stöckli J, Kolumam G, van Bruggen N, Gamble JR, Le Couteur DG, Cooney GJ, Andrikopoulos S, James DE.

Diabetes. 2014 Aug;63(8):2656-67. doi: 10.2337/db13-1665. Epub 2014 Apr 2.

8.

Th17 cells at the crossroads of autoimmunity, inflammation, and atherosclerosis.

van Bruggen N, Ouyang W.

Immunity. 2014 Jan 16;40(1):10-2. doi: 10.1016/j.immuni.2013.12.006.

9.

Mapping in vivo tumor oxygenation within viable tumor by 19F-MRI and multispectral analysis.

Shi Y, Oeh J, Eastham-Anderson J, Yee S, Finkle D, Peale FV Jr, Ross J, Hedehus M, van Bruggen N, Venook R, Ross S, Sampath D, Carano RA.

Neoplasia. 2013 Nov;15(11):1241-50.

10.

Targeting oxidized LDL improves insulin sensitivity and immune cell function in obese Rhesus macaques.

Li S, Kievit P, Robertson AK, Kolumam G, Li X, von Wachenfeldt K, Valfridsson C, Bullens S, Messaoudi I, Bader L, Cowan KJ, Kamath A, van Bruggen N, Bunting S, Frendéus B, Grove KL.

Mol Metab. 2013 Jun 11;2(3):256-69. doi: 10.1016/j.molmet.2013.06.001. eCollection 2013.

11.

Inhibition of VEGF-C modulates distal lymphatic remodeling and secondary metastasis.

Gogineni A, Caunt M, Crow A, Lee CV, Fuh G, van Bruggen N, Ye W, Weimer RM.

PLoS One. 2013 Jul 16;8(7):e68755. doi: 10.1371/journal.pone.0068755. Print 2013.

12.

Multimodal microvascular imaging reveals that selective inhibition of class I PI3K is sufficient to induce an antivascular response.

Sampath D, Oeh J, Wyatt SK, Cao TC, Koeppen H, Eastham-Anderson J, Robillard L, Ho CC, Ross J, Zhuang G, Reslan HB, Vitorino P, Barck KH, Ungersma SE, Vernes JM, Caunt M, Van Bruggen N, Ye W, Vijapurkar U, Meng YJ, Ferrara N, Friedman LS, Carano RA.

Neoplasia. 2013 Jul;15(7):694-711.

13.

Anti-inflammatory strategies for plaque stabilization after acute coronary syndromes.

Baruch A, van Bruggen N, Kim JB, Lehrer-Graiwer JE.

Curr Atheroscler Rep. 2013 Jun;15(6):327. doi: 10.1007/s11883-013-0327-7. Review. Erratum in: Curr Atheroscler Rep. 2013 Dec;15(12):374.

PMID:
23636864
14.

FDG-PET is a good biomarker of both early response and acquired resistance in BRAFV600 mutant melanomas treated with vemurafenib and the MEK inhibitor GDC-0973.

Baudy AR, Dogan T, Flores-Mercado JE, Hoeflich KP, Su F, van Bruggen N, Williams SP.

EJNMMI Res. 2012 May 31;2(1):22. doi: 10.1186/2191-219X-2-22.

15.

Death receptors DR6 and TROY regulate brain vascular development.

Tam SJ, Richmond DL, Kaminker JS, Modrusan Z, Martin-McNulty B, Cao TC, Weimer RM, Carano RA, van Bruggen N, Watts RJ.

Dev Cell. 2012 Feb 14;22(2):403-17. doi: 10.1016/j.devcel.2011.11.018.

16.

Amelioration of type 2 diabetes by antibody-mediated activation of fibroblast growth factor receptor 1.

Wu AL, Kolumam G, Stawicki S, Chen Y, Li J, Zavala-Solorio J, Phamluong K, Feng B, Li L, Marsters S, Kates L, van Bruggen N, Leabman M, Wong A, West D, Stern H, Luis E, Kim HS, Yansura D, Peterson AS, Filvaroff E, Wu Y, Sonoda J.

Sci Transl Med. 2011 Dec 14;3(113):113ra126. doi: 10.1126/scitranslmed.3002669.

17.

New imaging paradigms in drug development: the PET imaging approach.

Marik J, Bohorquez SM, Williams SP, van Bruggen N.

Drug Discov Today Technol. 2011 Summer;8(2-4):e63-9. doi: 10.1016/j.ddtec.2011.11.004.

PMID:
24990264
18.
19.

Granulocyte-colony stimulating factor promotes lung metastasis through mobilization of Ly6G+Ly6C+ granulocytes.

Kowanetz M, Wu X, Lee J, Tan M, Hagenbeek T, Qu X, Yu L, Ross J, Korsisaari N, Cao T, Bou-Reslan H, Kallop D, Weimer R, Ludlam MJ, Kaminker JS, Modrusan Z, van Bruggen N, Peale FV, Carano R, Meng YG, Ferrara N.

Proc Natl Acad Sci U S A. 2010 Dec 14;107(50):21248-55. doi: 10.1073/pnas.1015855107. Epub 2010 Nov 16.

20.

Noncompartmental kinetic analysis of DCE-MRI data from malignant tumors: Application to glioblastoma treated with bevacizumab.

Port RE, Bernstein LJ, Barboriak DP, Xu L, Roberts TP, van Bruggen N.

Magn Reson Med. 2010 Aug;64(2):408-17. doi: 10.1002/mrm.22399.

21.

Vessel imaging with viable tumor analysis for quantification of tumor angiogenesis.

Ungersma SE, Pacheco G, Ho C, Yee SF, Ross J, van Bruggen N, Peale FV Jr, Ross S, Carano RA.

Magn Reson Med. 2010 Jun;63(6):1637-47. doi: 10.1002/mrm.22442. Erratum in: Magn Reson Med. 2011 Mar;65(3):889. Magn Reson Med. 2012 Nov;68(5):1681-2. Corrected and republished in: Magn Reson Med. 2011 Mar;65(3):889-99.

22.

PlGF blockade does not inhibit angiogenesis during primary tumor growth.

Bais C, Wu X, Yao J, Yang S, Crawford Y, McCutcheon K, Tan C, Kolumam G, Vernes JM, Eastham-Anderson J, Haughney P, Kowanetz M, Hagenbeek T, Kasman I, Reslan HB, Ross J, Van Bruggen N, Carano RA, Meng YJ, Hongo JA, Stephan JP, Shibuya M, Ferrara N.

Cell. 2010 Apr 2;141(1):166-77. doi: 10.1016/j.cell.2010.01.033.

23.

Quantifying antivascular effects of monoclonal antibodies to vascular endothelial growth factor: insights from imaging.

O'Connor JP, Carano RA, Clamp AR, Ross J, Ho CC, Jackson A, Parker GJ, Rose CJ, Peale FV, Friesenhahn M, Mitchell CL, Watson Y, Roberts C, Hope L, Cheung S, Reslan HB, Go MA, Pacheco GJ, Wu X, Cao TC, Ross S, Buonaccorsi GA, Davies K, Hasan J, Thornton P, del Puerto O, Ferrara N, van Bruggen N, Jayson GC.

Clin Cancer Res. 2009 Nov 1;15(21):6674-82. doi: 10.1158/1078-0432.CCR-09-0731. Epub 2009 Oct 27.

24.

PET of glial metabolism using 2-18F-fluoroacetate.

Marik J, Ogasawara A, Martin-McNulty B, Ross J, Flores JE, Gill HS, Tinianow JN, Vanderbilt AN, Nishimura M, Peale F, Pastuskovas C, Greve JM, van Bruggen N, Williams SP.

J Nucl Med. 2009 Jun;50(6):982-90. doi: 10.2967/jnumed.108.057356. Epub 2009 May 14.

25.

Preclinical evaluation of carcinoembryonic cell adhesion molecule (CEACAM) 6 as potential therapy target for pancreatic adenocarcinoma.

Strickland LA, Ross J, Williams S, Ross S, Romero M, Spencer S, Erickson R, Sutcliffe J, Verbeke C, Polakis P, van Bruggen N, Koeppen H.

J Pathol. 2009 Jul;218(3):380-90. doi: 10.1002/path.2545.

PMID:
19334050
26.

Reactive hyperemia and BOLD MRI demonstrate that VEGF inhibition, age, and atherosclerosis adversely affect functional recovery in a murine model of peripheral artery disease.

Greve JM, Williams SP, Bernstein LJ, Goldman H, Peale FV Jr, Bunting S, van Bruggen N.

J Magn Reson Imaging. 2008 Oct;28(4):996-1004. doi: 10.1002/jmri.21517.

PMID:
18821600
27.

Molecular imaging in drug development.

Willmann JK, van Bruggen N, Dinkelborg LM, Gambhir SS.

Nat Rev Drug Discov. 2008 Jul;7(7):591-607. doi: 10.1038/nrd2290. Review.

PMID:
18591980
28.

Quantification of viable tumor microvascular characteristics by multispectral analysis.

Berry LR, Barck KH, Go MA, Ross J, Wu X, Williams SP, Gogineni A, Cole MJ, Van Bruggen N, Fuh G, Peale F, Ferrara N, Ross S, Schwall RH, Carano RA.

Magn Reson Med. 2008 Jul;60(1):64-72. doi: 10.1002/mrm.21470.

29.

Blocking vascular endothelial growth factor-A inhibits the growth of pituitary adenomas and lowers serum prolactin level in a mouse model of multiple endocrine neoplasia type 1.

Korsisaari N, Ross J, Wu X, Kowanetz M, Pal N, Hall L, Eastham-Anderson J, Forrest WF, Van Bruggen N, Peale FV, Ferrara N.

Clin Cancer Res. 2008 Jan 1;14(1):249-58. doi: 10.1158/1078-0432.CCR-07-1552.

30.

Bv8 regulates myeloid-cell-dependent tumour angiogenesis.

Shojaei F, Wu X, Zhong C, Yu L, Liang XH, Yao J, Blanchard D, Bais C, Peale FV, van Bruggen N, Ho C, Ross J, Tan M, Carano RA, Meng YG, Ferrara N.

Nature. 2007 Dec 6;450(7171):825-31.

PMID:
18064003
31.

Magnetic resonance angiography reveals therapeutic enlargement of collateral vessels induced by VEGF in a murine model of peripheral arterial disease.

Greve JM, Chico TJ, Goldman H, Bunting S, Peale FV Jr, Daugherty A, van Bruggen N, Williams SP.

J Magn Reson Imaging. 2006 Nov;24(5):1124-32.

PMID:
17029233
32.

Quantification of cortical bone loss and repair for therapeutic evaluation in collagen-induced arthritis, by micro-computed tomography and automated image analysis.

Barck KH, Lee WP, Diehl LJ, Ross J, Gribling P, Zhang Y, Nguyen K, van Bruggen N, Hurst S, Carano RA.

Arthritis Rheum. 2004 Oct;50(10):3377-86.

33.

A novel in vivo role for osteoprotegerin ligand in activation of monocyte effector function and inflammatory response.

Seshasayee D, Wang H, Lee WP, Gribling P, Ross J, Van Bruggen N, Carano R, Grewal IS.

J Biol Chem. 2004 Jul 16;279(29):30202-9. Epub 2004 May 15.

34.

Quantification of tumor tissue populations by multispectral analysis.

Carano RA, Ross AL, Ross J, Williams SP, Koeppen H, Schwall RH, Van Bruggen N.

Magn Reson Med. 2004 Mar;51(3):542-51.

35.

Zmpste24 deficiency in mice causes spontaneous bone fractures, muscle weakness, and a prelamin A processing defect.

Bergo MO, Gavino B, Ross J, Schmidt WK, Hong C, Kendall LV, Mohr A, Meta M, Genant H, Jiang Y, Wisner ER, Van Bruggen N, Carano RA, Michaelis S, Griffey SM, Young SG.

Proc Natl Acad Sci U S A. 2002 Oct 1;99(20):13049-54. Epub 2002 Sep 16.

36.

Can a small-molecular gadolinium contrast agent be applied successfully with dynamic MRI to quantitatively define brain tumor microvascular responses to angiogenesis inhibition?

Brasch RC, Gossmann A, Helbich TH, Kuriyama N, Roberts TP, Shames DM, van Bruggen N, Wendland MF, Israel MA.

Acad Radiol. 2002 Aug;9 Suppl 2:S326-7. No abstract available.

PMID:
12188263
37.

Vascular endothelial growth factor stimulates bone repair by promoting angiogenesis and bone turnover.

Street J, Bao M, deGuzman L, Bunting S, Peale FV Jr, Ferrara N, Steinmetz H, Hoeffel J, Cleland JL, Daugherty A, van Bruggen N, Redmond HP, Carano RA, Filvaroff EH.

Proc Natl Acad Sci U S A. 2002 Jul 23;99(15):9656-61. Epub 2002 Jul 12.

38.

Dynamic contrast-enhanced magnetic resonance imaging as a surrogate marker of tumor response to anti-angiogenic therapy in a xenograft model of glioblastoma multiforme.

Gossmann A, Helbich TH, Kuriyama N, Ostrowitzki S, Roberts TP, Shames DM, van Bruggen N, Wendland MF, Israel MA, Brasch RC.

J Magn Reson Imaging. 2002 Mar;15(3):233-40.

PMID:
11891967
39.

Dobutamine stress cine-MRI of cardiac function in the hearts of adult cardiomyocyte-specific VEGF knockout mice.

Williams SP, Gerber HP, Giordano FJ, Peale FV Jr, Bernstein LJ, Bunting S, Chien KR, Ferrara N, van Bruggen N.

J Magn Reson Imaging. 2001 Oct;14(4):374-82.

PMID:
11599061
40.

Apparent diffusion coefficient and MR relaxation during osmotic manipulation in isolated turtle cerebellum.

O'Shea JM, Williams SR, van Bruggen N, Gardner-Medwin AR.

Magn Reson Med. 2000 Sep;44(3):427-32.

41.

Increased binding activity at an antioxidant-responsive element in the metallothionein-1 promoter and rapid induction of metallothionein-1 and -2 in response to cerebral ischemia and reperfusion.

van Lookeren Campagne M, Thibodeaux H, van Bruggen N, Cairns B, Lowe DG.

J Neurosci. 2000 Jul 15;20(14):5200-7. Erratum in: J Neurosci 2000 Oct 1;20(19):7504.

42.

Transient focal cerebral ischemia induces sensorimotor deficits in mice.

Gerlai R, Thibodeaux H, Palmer JT, van Lookeren Campagne M, Van Bruggen N.

Behav Brain Res. 2000 Feb;108(1):63-71.

PMID:
10680758
43.

Secondary reduction in the apparent diffusion coefficient of water, increase in cerebral blood volume, and delayed neuronal death after middle cerebral artery occlusion and early reperfusion in the rat.

van Lookeren Campagne M, Thomas GR, Thibodeaux H, Palmer JT, Williams SP, Lowe DG, van Bruggen N.

J Cereb Blood Flow Metab. 1999 Dec;19(12):1354-64.

PMID:
10598940
44.

VEGF antagonism reduces edema formation and tissue damage after ischemia/reperfusion injury in the mouse brain.

van Bruggen N, Thibodeaux H, Palmer JT, Lee WP, Fu L, Cairns B, Tumas D, Gerlai R, Williams SP, van Lookeren Campagne M, Ferrara N.

J Clin Invest. 1999 Dec;104(11):1613-20.

45.

Evidence for a protective role of metallothionein-1 in focal cerebral ischemia.

van Lookeren Campagne M, Thibodeaux H, van Bruggen N, Cairns B, Gerlai R, Palmer JT, Williams SP, Lowe DG.

Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12870-5.

46.

High-resolution mapping of discrete representational areas in rat somatosensory cortex using blood volume-dependent functional MRI.

Palmer JT, de Crespigny AJ, Williams S, Busch E, van Bruggen N.

Neuroimage. 1999 Apr;9(4):383-92.

PMID:
10191167
47.

Protein targeting in the analysis of learning and memory: a potential alternative to gene targeting.

Gerlai R, Williams SP, Cairns B, Van Bruggen N, Moran P, Shih A, Caras I, Sauer H, Phillips HS, Winslow JW.

Exp Brain Res. 1998 Nov;123(1-2):24-35.

PMID:
9835389
48.

High-resolution functional magnetic resonance imaging of the rat brain: mapping changes in cerebral blood volume using iron oxide contrast media.

van Bruggen N, Busch E, Palmer JT, Williams SP, de Crespigny AJ.

J Cereb Blood Flow Metab. 1998 Nov;18(11):1178-83.

PMID:
9809506
49.

Magnetic resonance imaging assessment of cerebral hemodynamics during spreading depression in rats.

de Crespigny A, Röther J, van Bruggen N, Beaulieu C, Moseley ME.

J Cereb Blood Flow Metab. 1998 Sep;18(9):1008-17.

PMID:
9740104
50.

Magnetic resonance imaging detects suppression of tumor vascular permeability after administration of antibody to vascular endothelial growth factor.

Pham CD, Roberts TP, van Bruggen N, Melnyk O, Mann J, Ferrara N, Cohen RL, Brasch RC.

Cancer Invest. 1998;16(4):225-30.

PMID:
9589031

Supplemental Content

Loading ...
Support Center